In the last trading session, 0.95 million Organogenesis Holdings Inc (NASDAQ:ORGO) shares changed hands as the company’s beta touched 1.63. With the company’s per share price at $3.03 changed hands at $0.15 or 5.21% during last session, the market valuation stood at $384.37M. ORGO’s last price was a discount, traded about -121.45% off its 52-week high of $6.71. The share price had its 52-week low at $2.28, which suggests the last value was 24.75% up since then.
Analysts gave the Organogenesis Holdings Inc (ORGO) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.50. If we narrow down to specifics, the data shows that 0 out of 3 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended ORGO as a Hold, 3 felt it is a Buy and 0 rated the stock as Underweight. Organogenesis Holdings Inc’s EPS for the current quarter is expected to be -0.01.
Organogenesis Holdings Inc (NASDAQ:ORGO) trade information
Instantly ORGO was in green as seen at the end of in last trading. With action 10.58%, the performance over the past five days has been green. The company’s shares are showing year-to-date downside of -5.31%, with the 5-day performance at 10.58% in the green. However, in the 30-day time frame, Organogenesis Holdings Inc (NASDAQ:ORGO) is -41.51% down.
The consensus price target for the stock as assigned by Wall Street analysts is 6, meaning bulls need an upside of 49.5% from its current market value. According to analyst projections, ORGO’s forecast low is 6 with 6 as the target high. To hit the forecast high, the stock’s price needs a -98.02% plunge from its current level, while the stock would need to soar -98.02% for it to hit the projected low.
Organogenesis Holdings Inc (ORGO) estimates and forecasts
Year-over-year growth is forecast to reach 2.37% up from the last financial year.
Consensus estimates given by 3 financial analysts project the company’s revenue in the current quarter to hit an average of 103.4M. 3 analysts are of the opinion that Organogenesis Holdings Inc’s revenue for the current quarter will be 142.8M. The company’s revenue for the corresponding quarters a year ago was 130.23M and 115.18M respectively. According to analysts, the company will likely register a growth in its current quarter sales, forecast at -20.60%. The estimates for the next quarter sales put growth at 23.98%.
The 2025 estimates are for Organogenesis Holdings Inc earnings to increase by 754.67%.
ORGO Dividends
Organogenesis Holdings Inc is expected to release its next quarterly earnings report in July.
SOLEUS CAPITAL MANAGEMENT, L.P. holds the second largest percentage of outstanding shares, with 8.6888% or 11.52 million shares worth $32.25 million as of 2024-06-30.
Among Mutual Funds, the top two as of Mar 31, 2025 were VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and iShares Trust-iShares Russell 2000 ETF . With 1.82 shares estimated at $5.53 million under it, the former controlled 1.44% of total outstanding shares. On the other hand, iShares Trust-iShares Russell 2000 ETF held about 1.36% of the shares, roughly 1.73 shares worth around $5.23 million.
